As part of its quest to successfully develop stem cells for
research and therapy, the International Stem Cell Corporation (OTCQB: ISCO) has
been using a powerful new stem cell technology to address the problem of
immune-rejection. Most recently, the Carlsbad, California-based company has
been focused on utilizing parthenogenesis to advance the field of regenerative
medicine.
Parthenogenesis is a process that uses unfertilized human
eggs to create a new class of pluripotent human stem cells. These stem cells,
known as human parthenogenetic stem cells (hpSCs), are specialized because they
can be immune-matched to millions of people, and a small number of hpSC lines
alone can provide enough immune-matched cells for a large fraction of the
world’s population. HpSCs also have the added benefit of retaining many of the
advantages usually linked to embryonic stem cells while circumventing the
ethical issues.
By relying on its novel business model consisting of a
number of revenue-generating subsidiaries, including Lifeline Cell Technology
and Lifeline Skin Care, ISCO has been developing therapeutic products from its
own intellectual property for years.
Thanks to the creation of the UniStemCell bank, the
foundation of ISCO’s research and the globe’s greatest collection of
non-embryonic histocompatible human stem cells used for research and commercial
use, ISCO has been able to innovate in the area of therapeutics. The company,
which is committed to developing stem cell treatments for neurological
disorders, liver diseases and blindness caused by corneal damage, has been able
to focus its hpSCs research efforts on treating these diseases and disorders,
especially in areas where cellular replacement has been shown to be effective
clinically, but there is a limited or no viable source of safe, ethical cells
to treat patients.
At the same time, Lifeline Skin Care, a wholly-owned ISCO
subsidiary and cosmeceutical business, has been developing, manufacturing and
marketing cosmetic skin care products using a proprietary extract derived from
the company’s pluripotent stem cells. Lifeline Cell Technology, another
wholly-owned subsidiary and research products business, has also been creating,
manufacturing and marketing human cell culture products, including frozen human
“primary” cells and the reagents (media) needed to grow, maintain and
differentiate the cells.
So not only has ISCO’s research and development team been
using its hpSCs to make important breakthroughs in the treatment of a number of
serious diseases, the company has also developed two successful business units
which generate revenues from the sale of products that employ ISCO’s scientific
discoveries.
For more information, visit www.internationalstemcell.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
